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ABSTRACT
Tumors are composed of different types of cancer cells that contribute to tumor heterogeneity.
Among these populations of cells, cancer stem cells (CSCs) play an important role in cancer initia-
tion and progression. Like their stem cells counterpart, CSCs are also characterized by self-renewal
and the capacity to differentiate. A particular population of CSCs is constituted by mesenchymal
stem cells (MSCs) that differentiate into cells of mesodermal characteristics. Several studies have
reported the potential pro-or anti-tumorigenic inﬂuence of MSCs on tumor initiation and progres-
sion. In fact, MSCs are recruited to the site of wound healing to repair damaged tissues, an event
that is also associated with tumorigenesis. In other cases, resident or migrating MSCs can favor
tumor angiogenesis and increase tumor aggressiveness. This interplay between MSCs and cancer
cells is fundamental for cancerogenesis, progression, and metastasis. Therefore, an interesting
topic is the relationship between cancer cells, CSCs, and MSCs, since contrasting reports about
their respective inﬂuences have been reported. In this review, we discuss recent ﬁndings related
to conﬂicting results on the inﬂuence of normal and CSCs in cancer development. The understand-
ing of the role of MSCs in cancer is also important in cancer management. STEM CELLS TRANSLA-
TIONAL MEDICINE 2017;6:2115–2125
SIGNIFICANCE STATEMENT
There is no doubt that mesenchymal stem cells (MSCs) can have strong effects on the outcome
of tumor development and progression. The reasons by which the effects have been seen as
suppressive or stimulating of cancerogenesis, also remain controversial. MSCs may act on all
phases of carcinogenesis such as the generation of cancer stem cells (CSCs), epithelial-to-
mesenchymal transition (EMT), angiogenesis, drug resistance, and metastasis. On the other
hand, there are several studies that reported suppressive effects of MSCs on cancer cells. The
discrepancy between these results may arise from issues that are related to tissues origin, indi-
vidual genetic variability of patients, and cancer typology. Moreover, it is important to consider
also the experimental variability due to different cancer cell lines used, MSCs origin, and differ-
ent models of CSCs. Thus, clarifying the key role of MSCs in cancer development, or determin-
ing their potential use in cancer treatment, appears to be challenging. In this regard, in depth
knowledge of key factors or mechanisms that control the pro- or anticancer effects of MSCs on
cancer progression will certainly provide answers to the above questions. In addition, it is
important to evaluate the significance of resident MSCs in cancer. In summary, to achieve a bet-
ter treatment of patients, future clinical approaches will need to use strategies that inhibit or
modulate the dialog between MSCs and cancer cells.
INTRODUCTION: STEM CELLS AND CANCER
STEM CELLS
What Are Stem Cells and Mesenchymal
Stem Cells?
Stem cells are characterized by the capacity to
self-renew and to generate differentiated proge-
nies. The regulation of these processes is
fundamental for the maintenance of the stem cell
pool within a tissue [1]. Cells capable to differenti-
ate into mesodermal-derived tissues, such as adi-
pocytes, chondrocytes, and osteoblasts, are called
mesenchymal stem cells (MSCs) and they are sug-
gested to reside in all human organs and tissues
[2]. Several studies report also that MSC can circu-
late in the peripheral blood [3] and are detected
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CANCER STEM CELLS
in tissues other than bone marrow, such as subcutaneous fat (adi-
pose stem cells [ASCs]) [4, 5], periodontal ligament [6], umbilical
cord blood [7], fetal tissues [8], lymph nodes [9], and adult spleen
and thymus [10], thus hypothesizing a “mesenchymal organ-
ization,” virtually present in all post-natal organs and tissues [11].
Some reports describe that MSCs can also differentiate in non-
mesodermal cell types, such as gut and skin epithelial cells, hepa-
tocytes, pneumocytes, and neuronals [12–15]. However, there is a
lack of accuracy regarding to both terminology and biological char-
acteristics. Many authors state that MSCs are considered different
from so-called multipotent adult progenitor cells that are able to
differentiate into neurons, epithelial cells, as well as in cells of
mesenchymal origin [12]. Another typology of stem cells, different
from MSCs, are multipotent mesenchymal stromal cells from
which derive only cells belonging to mesodermal tissues, such as
fat, muscle, bone, and cartilage cells [16]. Such differences both in
terminology and biological characteristics home probably in the
variability of experimental methodologies, rather than in the exis-
tence of different stem cells of mesenchymal origin, although it is
possible to hypothesize that it can exist a gradient of MSC differ-
entiation as well as demonstrated for hematopoietic stem cell pre-
cursors. MSCs are rare with 1/105 cells in bone marrow and lose
their differentiation potential after 40 doublings [17]. These cells
are also able to migrate from the circulation to different tissues in
response to a variety of signals. This process is called “homing”
and is regulated by a speciﬁc pattern of chemokines and chemo-
kine’s receptors [2]. Indeed, MSCs are recruited to the site of
wound healing to repair injured tissues in a similar process than
the one found in tumors. On the other hand, inﬂammation con-
tributes to tumourigenesis and metastasis through the homing
process. In this contest, it is also important to consider the role of
immune cells, including macrophages, lymphocytes, monocytes,
and dendritic cells. In fact, the immune system has both stimula-
tory and inhibitory effects on tumor initiation, development, and
metastasis formation, and the balance of these responsiveness
can depend on the different tumor microenvironments [18]. Thus,
the interplay among epithelial cancer and stromal cells and
immune compartment is fundamental for cancerogenesis, pro-
gression, and metastasis, and may lead to a different biological
behavior of tumor cells during the cancer progression [19].
What Are ASCs?
An interesting source of MSCs is the adipose tissue that originates
adipose-derived mesenchymal stem cells (ASCs). These cells are
similar to bone marrow-derived MSCs, are multipotent and are
capable to differentiate into mesenchymal lineages [19]. Never-
theless, there are little differences in their immunophenotype, dif-
ferentiation ability, proteome, immunomodulatory properties,
and transcriptome. Some differences about speciﬁc characteristics
of MSCs and ASCs, other than intrinsic heterogeneity, can be due
to different isolation and culture experimental methodologies.
ASCs are more stable in long-term cultures, show a major viability
and minor senescence, have a higher proliferation ability and
maintain a high rate of differentiation in long-term culture with
respect to MSCs [20, 21]. Moreover, it has been demonstrated
that ASCs sustain hematopoiesis with major efﬁcacy compared to
MSCs [21]. Regarding to immunophenotype, ASCs express the
CD34 marker decreasing during differentiation as well as CD54
and CD49d. MSCs do not express CD34, show low expression of
CD54 and CD49d [22–24] (Supporting Information Table S1).
Moreover, the same ASCs can be different on the basis of their
origin (visceral vs. subcutaneous fat). Some studies reported that
subcutaneous ASCs are different from visceral ASCs in terms of
morphology, and multipotent differentiation potential [25] and,
consequently, have a different biological behavior with cancer
cells. Subcutaneous ASCs show a ﬁbroblast like shape and are able
to home to cancer cells, while visceral ASCs are similar to epithe-
lial cells and more able to differentiate. Then, visceral ASCs are
more able to proliferate, induce epithelial to mesenchymal transi-
tion activating the PI3K/AKT signaling, improve migration, and
invasion of breast cancer cells secreting IL-6 and IL-8 compared to
subcutaneous ASCs [25]. This is important in delineating the corre-
lation between ASCs origin and cancer progression.
What Are Cancer Stem Cells?
Observations dating back to more than 50 years have evidenced
similarities between cancer and embryonic development and that
led to the hypothesis of the existence of cancer stem cells (CSCs).
Recent growing evidences suggest that the tumor is composed of
heterogeneous populations of cells with different levels of malig-
nity and the tumor development is driven by a specialized cell
subset, characterized by self-renewing, multi-potent, and tumor-
initiating properties [26] (Supporting Information Table S2). These
malignant cells are called CSCs and their maintenance is tightly
ensured by the microenvironment and the stroma. They are prob-
ably generated from normal stem or precursor cells within tissues
after mutations occur and are typically resistant to conventional
treatments [26, 27] (Fig. 1). This model has been studied and dem-
onstrated especially for hematological diseases. For solid tumors,
it is very difﬁcult to establish a detailed tumor hierarchy due to
the loss of speciﬁc markers for CSCs. Many of markers used to
deﬁne the CSCs of solid tumors fail in selecting this subpopulation.
For example, CD133 marker has been the ﬁrst marker used for iso-
lating CSCs from colon carcinoma. Recently, some studies
reported that metastatic colon carcinoma cells negative to CD133
are able to recapitulate the tumor as well as those positive for
CD133 [28, 29]. Then, Brabletz et al. [30] have demonstrated that
in colon cancer there are two stem subpopulations: one, able to
initiate the tumor, deﬁned “resident cancer stem cells” subset and
another, able to propagate the tumor forming metastasis deﬁned
“migrating stem cells” subpopulation. Thus, several studies dem-
onstrated that within of CSCs could exist a speciﬁc hierarchy
[26–30]. Consequently and on the basis of these uncertainties, a
different terminology in deﬁning CSCs is used as “tumor initiating
cells” or “tumor propagating cells.” Moreover, it has been
hypothesized that there is an alternative, but not exclusive, model
of carcinogenesis based on the fact that the tumor could be made
up of different heterogeneous clones of tumor cells with different
mutational proﬁles that represent different phases of tumourigen-
esis [31]. This model takes in consideration the effect of microen-
vironment on each clone in terms of growth and development.
On the other hand, late relapse of cancer provides a direct conﬁr-
mation for the existence and the persistence of tumor initiating
cells at a subclinical level [32]. This is deﬁned cancer dormancy. In
this context, Zimmerlin et al. [32] reported that MSCs signals have
different effects on dormant and resting tumor initiating breast
cancer cells. In particular, they demonstrated that ASCs enhance
the growth of active, but not resting cells. However, the CSC’s
model still is a controversial theme and object of debate. In these
scenarios, the CSCs ﬁeld needs to be deeply explored for under-
standing the carcinogenesis and address new therapeutic strat-
egies. ASCs have been used as tissue repair promoters and in
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several clinical ﬁelds, including cardiac, orthopedic, plastic, bone,
and breast surgery [33–35]. They have been identiﬁed as optimal
and potential candidates for tissue reconstruction in patients with
oncological history. Delay et al. [36] reported a cohort of 880
breast reconstruction using autologous fat. This cohort included
also patients with history of breast cancer and no cancer develop-
ment was detectable with a follow up of 10 years [36]. The same
results were reported by other studies [37–39]. However, despite
optimal esthetic results, some reports have suggested that MSCs
could promote cancer recurrence [19, 40, 41]. In fact, ASCs could
active and improve the growth of resting and residual breast can-
cer cells after surgery in breast cancer patients. In this context, an
interesting and still poorly explored research topic is the one deal-
ing with the relationship between cancer cells, CSCs, and MSCs.
Since we have contrasting reports about their respective inﬂuen-
ces, some evidences suggest an antagonistic effect of normal cells
on cancer cells, while others have evidenced that MSCs can favor
cancer proliferation, invasion, and metastasis. In this review, we
aim to discuss and provide up-to date data on this exciting topic.
THE ROLE OF MSCS IN NEOPLASTIC MICROENVIRONMENT
It is well-known that interactions between cancer cells and stroma
are of fundamental importance in promoting both the develop-
ment and invasiveness of tumors. For instance, cancer cells may
lead to modiﬁcations of topography and molecular composition
of stroma during early tumor development and this, in turn, can
affect the properties of the cancer cells [42]. Therefore, the bidir-
ectional interplay between cancer cells and cells of stroma, includ-
ing MSCs, endothelial, immune, and ﬁbroblast-like stromal cells,
plays a key role in tumor progression and metastasis and creates a
complex microenvironment called tumor niche (Fig. 2). In normal
stroma, predominant cells are ﬁbroblasts that secrete an extracel-
lular matrix (ECM) providing a natural barrier against tumor pro-
gression [43, 44]. On the other hand, the ECM is able to support
and promote tumor progression by modiﬁcations of the same
ECM [45]. In this context, both ﬁbroblasts and myoﬁbroblasts,
denominated cancer-associated ﬁbroblasts (CAFs) produce pro-
teins such as collagen, ﬁbronectin, a-smooth muscle actin, and
others, creating alterations of ECM architecture. As a result, the
cancer cells start to change their morphology becoming invasive
and metastatic [46] as it has been described in some studies of
breast [47] and pancreatic cancers [48]. In these processes, MSCs
can be fundamental. It has been reported that MSCs can originate
from tumor resident stroma progenitors, or can be recruited from
other tissues as bone marrow by circulation [49]. Interestingly,
MSCs have the tendency to migrate into damaged tissues or
organs, driven by chemotactic gradients of cytokines/chemokines
released from same damaged tissues. Once arrived in injured
sites, MSCs provide structural support and secrete factors for tis-
sue repair [50]. Therefore, this physiological behavior happens
also for the tumor that can be considered as a “wounds that never
heal” [51]. Circulating MSCs from bone marrow, adipose tissue or
MSCs derived from tumor stroma cells that are able to differenti-
ate in CAFs [52].
In a model of inﬂammation-induced gastric cancer, MSCs gen-
erated CAFs that were recruited to tumor microenvironment in a
process that was mediated by TGF-b and SDF-1a [53]. In an osteo-
sarcoma model, it was found that cancer cells were able to inhibit
the osteogenic differentiation of MSCs through TGF-b/Smad2/3
signaling and to increase their production of vascular endothelial
growth factor (VEGF) and IL-6 and other pro-tumor cytokines. In
this case, MSCs derived from femur fracture patients undergoing
orthopedic surgery. Moreover, TGFb-mediated inhibition of osteo-
genic differentiation was developed through increased expression
of b-catenin [54]. Interestingly in breast cancer, the axis SDF-1a/
CXCR4 is crucial in the interaction between breast cancer cells and
MSCs of bone marrow. Breast cancer cells are able to attract mar-
row derived MSCs and in turn, breast cancer cells preferentially
metastasize to the bone marrow. In both cases, SDF-1a seems to
be involved [55]. The same axis is probably important also to guide
Figure 1. Model of CSCs theory: only CSCs are able to form and sustain tumor and are resistant to conventional therapies. CSCs are gener-
ated from normal stem cells or precursor/progenitor cells where epigenetic mutations are occurred. Abbreviation: CSC, cancer stem cell.
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the interaction between cancer cells and adipose-derived stem
cells [56].
Another key feature of cancer is that the metabolism is an
anaerobic glycolysis even under aerobic conditions. It has been
demonstrated that osteosarcoma cells induce oxidative stress with
reactive oxygen species (ROS) production in adipose MSCs. This also
induces a shift to aerobic glycolysis with MSCs producing lactates.
Furthermore, cancer cells can increase their mitochondria mass and
activity and consequently increase their energetic metabolism [57,
58]. MSCs can also regulate the metabolism of cancer cells through
secretion of exosomes [59]. In a recent study, exosomes produced
from the prostate cancers can inhibit the adipogenic differentiation
of MSCs, favoring the differentiation of MSCs into myoﬁbroblasts
[60]. In turn, the exosome differentiated MSCs stimulate angiogene-
sis and tumor growth [60]. Some studies describe two classes of
polarized MSCs depending on expression of Toll like receptors (TLR).
TLR4 primed-MSCs are deﬁned MSCs1 and are polarized into pro-
inﬂammatory phenotype. They are able to inhibit tumor growth
and metastasis. TLR3 primed MSCs are deﬁned MSCs2 and have the
classic immunosuppressive phenotype. They are capable to improve
the tumor growth and favor metastasis formation. This classiﬁcation
depends on the cytokine proﬁle expressed from speciﬁc MSCs and
include over-expression of TGFb, and SMAD3–4 [61].
Different types of immune cells are also identiﬁable within
the tumor microenvironment. These cells play both stimulatory
and inhibitory roles on cancer growth. Both T-cells and B-cells inﬁl-
trations may represent an important favorable prognostic factor,
as it was demonstrated in melanoma, colorectal, breast, and ovar-
ian cancers [62, 63].
During tumor progression, another class of immune cells to
be considered are macrophages. In fact, monocytes and macro-
phages can be recruited into tumors site altering the tumor
microenvironment and accelerating tumor progression [64]. Mac-
rophages shift their phenotypes in response to various microenvir-
onmental signals generated both from tumor and stromal cells.
Macrophages can be subdivided into two categories: classic M1
and alternative M2 macrophages [65]. The M1 macrophage is
involved in the inﬂammatory response, pathogen clearance, and
antitumor immunity. On the contrary, the M2 macrophage is
involved in an anti-inﬂammatory response, wound healing, and
has pro-tumorigenic properties. The tumor-associated macro-
phages (TAMs) closely resemble the M2-polarized macrophages
and are critical modulators of the tumor microenvironment. Sev-
eral studies have suggested that TAM accumulation in tumors cor-
relates with a poor clinical outcome and provide a favorable
microenvironment to support tumor development and progres-
sion regulating tumor angiogenesis, invasion, metastasis, immuno-
suppression, and chemotherapeutic resistance [64–66]. Together,
MSCs and TAMs promote tumor growth. In fact, MSCs can pro-
mote tumor progression increasing recruitment of TAMs in tumor
site via CCR2 [64]. Another chemokine produced by MSCs, able to
recruit the TAM is CCL2 [67]. Thus, MSCs and TAMs can engage in
a bidirectional interaction resulting in tumor promotion and pro-
gression. Last, a very important characteristic to consider is that
tumor microenvironment is not static but is actually dynamic by
being the result of continuous tissue remodeling, tumor metabolic
changes, recruitment of circulating stromal and immune cells, and
a result of changes induced by anticancer agents.
INTERACTION AMONG MSCS, CANCER CELLS, AND CSCS
CSCs features are mainly represented by tumor-initiating capacity,
metastatic potential, and drug resistance. Some studies have
reported that MSCs can increase the CSCs population within a
Figure 2. Tumor microenvironment consists not only of tumor cells and CSCs but are involved several types of cells and or processes, such
as ﬁbroblasts, migration of immune cells, angiogenesis, and matrix remodeling, MSCs thereby generating the so-called tumor niche. There-
fore, cancer cells and CSCs are intimately in contact with these cells, promoting tumourigenesis and cancer progression through several
mechanisms among which tissue remodeling through matrix metalloproteinases, deposition of different extracellular matrix, liberation of
pro-angiogenic molecules, and secretion of soluble factors. Abbreviations: BMDC, bone-marrow derived cells; CAF, cancer-associated ﬁbro-
blast; CSC, cancer stem cell; EPC, endothelial progenitor cells; MSC, mesenchymal stem cell.
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tumor [68]. Bone morphogenetic proteins (BMPs) are among the
molecules that are responsible for stemness and drug resistance. In
ovarian cancer, the number of CSCs can be increased by MSCs iso-
lated from human ovarian tumor ascites via BMP2 and BMP4 [68].
The latter could also be produced in response to Hedgehog (Hh)
secretion by ovarian cancer cells with potential mediation in resist-
ance to chemotherapeutic drugs [69]. In breast cancer cells, MSCs
induce an increase of mir-199 and mir-214 leading to a repression
of FoxP2 expression.This, in turn, promotes metastasis andmainte-
nance of cancer stemness phenotype of breast cancer cells [70].
There are several chemokines and cytokines produced by MSCs
that get a key role in modulating CSCs and cancer cells. MSCs pro-
duce PGE2 after stimulation of IL-1a and IL-1b secreted by colon
cancer cells. This leads to a secretion of IL-6, CXCL1, and CXCL8 by
MSCs increasing stemness characteristics of colon cancer cells [71].
Other studies have reported that MSCs are able to increase the
number of breast cancer cells positive to aldehyde dehydrogenases
(ALDH) by secretion of CXCR2 ligands [72]. Conditioned media
derived from MSCs culture includes speciﬁc cytokines such as IL-6
and CXCL8 able to induce expression of Oct4 and Sox2 in colorectal
cancer cells [73]. Moreover, another study demonstrated that IL-6
secreted by MSCs leads to an increase of CSCs expressing CD133 in
colorectal cancer cells by JAK2-STAT3 pathway [74]. Moreover, in
prostate cancer, it has been observed that after bone marrow-mes-
enchymal stem cells (BM-MSCs) inﬁltration in tumor, CCL5
increases, leading to a strong expansion of CSCs, that, in turn, indu-
ces an over-expression of matrix metalloproteinase 9, ZEB-1,
CD133, and CXCR4 molecules. CCL5 secreted by MSCs promotes
also proliferation of breast cancer cell lines [75] and invasion [76].
Irradiated breast cancer cells increase the release of TGFb1, VEGF,
and platelet-derived growth factor BB (PDGF-BB), which trigger the
migration of MSCs (in this case from a murine model) to cancer
cells through the upregulation of CCR2 [77]. Other factors secreted
by MSCs, important in the interaction of cancer cells can be CXCL1,
CXCL5, 6 and 7, IL4, IL8, IL10, IL17b, S100A4, and EGF (Fig. 3). The
pattern of chemokines axis is strictly dependent on tumor cell types
and niches. Besides chemokines effects, there are other types of
interactions that exist between cancer cells and MSCs. These are
carried out through exosomes and small secreted vesicles that are
implicated in intercellular communications which may also have a
role in cancerogenesis, either directly or in cooperation with che-
mokines. For instance, exosomes secreted by cholangiocarcinoma
cells promote the migration of human bone-marrow derived MSCs
to cancer cells via the release of CXCL1 and other cytokines from
the same MSCs [78]. Another mechanism involves the urokinase
plasminogen activator, that is expressed and released by a variety
of solid tumor cell lines (brain, lung, prostate, and breast) and
which plays a role in the migration of MSCs to the tumor site [75].
On the other hand, there are some observations in a murinemodel
underlining the possibility that MSCs could have also an antiproli-
ferative effect on cancer cells by upregulating the expression of
p21 and caspase-3 and therefore leading to G0-G1 arrest and apo-
ptosis of cancer cells [79]. Adipose-derived MSCs from human
healthy donors were shown to produce interferon-b (IFN-b) which,
through STAT1 activation, signiﬁcantly induced apoptosis and sup-
pressed the proliferation of some breast and lung cancer cell lines
[80]. We reported that in cocultures of breast and osteosarcoma
cell lines (MCF7 and SAOS2, respectively) with adipose-derived
MSCs derived from patients undergoing esthetic surgery, the latter
did not differentiate andmaintain the stemness phenotype in vitro,
whereas the co-injection of MSCs and MCF7 in murine models led
to an increase of tumor size and vascularization compared to con-
trols [19]. Moreover, cancer cells increased the proliferation of
adipose-derived MSCs that led us to hypothesize that cancer cells
may contribute to the maintenance of the resident stem popula-
tion, which could give them an advantage in terms of aggressive-
ness. The maintaining of stemness features of resident stem cells
was conﬁrmed by the absence of epithelial-mesenchymal-transi-
tion (EMT). EMT and mesenchymal-epithelial-transition (MET) are
processes by which the cells undergo molecular and structural
changes and migrate to other sites in the body. Therefore, it has
been demonstrated that there are different types of stem cell pop-
ulations: one resident and deﬁned as stationary stem cell popula-
tion that is involved in the maintenance of tissues homeostasis,
and the other deﬁned as migratory stem cells that able to migrate
and invade. Based on these considerations, we hypothesize that
our stem cells are stationary and are not undergoing EMT.We could
consider that cancer cells could directly maintain the adipose-
derived MSCs population present in the tumor microenvironment,
independently from the activation of homing/migration signals
and without the necessity to recruit bone-marrow derived MSCs.
Endothelial/pro-angiogenic factors were downregulated in cocul-
tured cells in vitro, thus stressing the concept of a speciﬁc cancer-
Figure 3. MSCs secretome and tumor stemness. MSCs release sev-
eral factors that can induce stemness and drug resistance or main-
tain the CSCs phenotype. MSCs produce BMP4 and 2 increasing
CSCs number in ovarian cancer. CSCs, in turn, activate Hh pathway.
MSCs can induce an increase of mir-199 and mir-214 leading to a
repression of FoxP2 promoting metastasis and maintenance of CSCs
phenotype. IL-1a and IL-1b secreted by cancer cells induce the pro-
duction of PGE2, IL6, and IL8 by MSCs. This leads to a secretion of
IL-6, CXCL1, and CXCL8 by MSCs increasing stemness characteristics.
MSCs are able to increase the number of breast cancer cells positive
to ALDH by secretion of CXCR2 ligands inducing expression of Oct4
and Sox2. IL-6 secreted by MSCs leads to an increase of CSCs
expressing CD133 by JAK2-STAT3 pathway. Irradiated breast cancer
cells increase the release of TGFb1, VEGF, and PDGF-BB, which acti-
vate the migration of MSCs to cancer cells. Moreover, cocultures of
MSCs with breast cancer cells increases the production of CXCR2
ligands including CXCL1, 5, 6, 7, and 8 that are able to increase the
percentage of CSCs. Also, IL-10, IL-17b, and EGF, secreted by MSCs,
are involved in increasing breast CSCs number. MSCs can also lead
to an increase of CCL5 expression that, in turn, induce an increase
of CSCs by upregulation of ZEB1, MMP9, and CD133 in prostate
cancer. MSCs can also regulate the metabolism of CSCs through
secretion of exosomes in breast cancer and cholangiosarcomas.
Abbreviations: ALDH, aldehyde dehydrogenases; CSC, cancer stem
cell; EGF, endothelial growth factor; HH, hedgehog; MSC, mesenchy-
mal stem cell; PDGF-BB, platelet-derived growth factor BB; VEGF,
vascular endothelial growth factor.
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induced stemness maintenance. In vivo assays, we have demon-
strated that adipose-derived MSCs, co-injected with MCF7 breast
cancer cells, were integrated in tumor microenvironment, thus
leading to more proliferating, bigger and clearly vascularized
tumors in nude mice [19]. Therefore, although it is well recognized
that there is a bidirectional interplay between MSCs and cancer
cells, speciﬁc mechanisms involved in promoting or inhibition of
tumor growth fromMSCs remain poorly established.
IMMUNE SYSTEM AND CSCS: IMPLICATIONS FOR
IMMUNOTHERAPY
A lot of research has focused on the role of the immune system in
preventing tumor growth and on the other hand on the ability of
cancer cells to escape the immune system [81]. The investigational
efforts have led to the clinic several drugs targeting immune check-
points such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and pro-
grammed cell death/ligand-1 (PD-1/PD-L1), with impressive results
[82]. Nevertheless, in many cases, these drugs do not act against
the tumor or they are effective for short times. CSCs, besides being
chemo- and radio-resistant, are also immune-resistant. For example,
in many cases, they lack the expression of human leukocyte antigen
(HLA) class I, so escaping the killing mediated by T lymphocytes [81].
Moreover, CSCs have been demonstrated to release soluble factors
with immunomodulatory properties, such as IL-10, IL-13, TGF-b,
and others that can make the tumor microenvironment insensible
to the effector immune cells [83]. The same tumor niche can host
Treg cells and suppressive M2 macrophages. On the other hand,
some studies have identiﬁed on CSCs the expression of activator
natural killer (NK) receptors ligands, thus implying a probable sensi-
tivity of CSCs by NK cells [84]. These ﬁndings could open the way to
new therapeutic approaches, exploiting NK. Besides CSC them-
selves, human MSCs have been reported to partially express major
histocompatibility complex class I and to lack the expression of HLA
class II antigens, that may result in a non-immunogenic phenotype.
Moreover, MSCs have been described as having immunosuppres-
sive properties by modulating both T-cell and B-cell functions [2]. It
seems reasonable to speculate that one of the mechanism of inter-
action between cancer cells and CSCs could be inﬂuenced by the
immune system. In the last years, a lot of research has focused on
the immunomodulatory effects of MSCs, since these cells can be
found around vascular areas of the bone marrow, which could have
a negative effect on cytotoxic T cells [85]. Although these mecha-
nisms are misunderstood, MSCs have been reported to exert an
immune-suppressive effect. A probablemechanismmay involve the
demonstrated capacity of MSCs to migrate from bone marrow, adi-
pose tissue and other sites, and to the tumor where they directly
inﬂuence tumor microenvironment and tumor growth. Another
mechanism may involve MSCs-mediated recruitment and mainte-
nance of regulatory Tcells (Tregs) resulting in cytotoxic T cells nega-
tive regulation, as it was demonstrated using bone marrow aspirate
from healthy subjects [85]. This expansion has been attributed to
the secretion of TGF-b byMSCs [85]. Besides favoring the expansion
of Tregs, it has also been demonstrated that MSCs can induce a
switch in favor of Th2-type CD41 T cells that increases expression
levels of IL-10 and decreases the activity of NK cells [85, 86].
EFFECT OF MSCS ON EMT AND METASTASIS FORMATION
EMT is a process through which cancer cells acquire an invasive
phenotype that leads to metastasis. Some reports indicate a key
role of MSCs in causing EMT. Human bone marrow-derived MSCs
have been reported to promote EMT in pancreatic cancer cells
through Notch signaling [87]. In luminal breast cancer, adipose-
derived MSCs from women undergoing breast reconstruction
could induce an overexpression of EMT related genes as they
expressed several TGF-b-related BMP [88]. The way through which
MSCs exert a role on tumor invasion, is not completely elucidated.
In a coculture model of breast cancer cells with MSCs, it was
shown that the latter enhanced the elongation, directional migra-
tion, and traction of cancer cells. This process was mediated by
human MSCs-secreted TGF-b, migratory proteins rho-associated
kinase, focal adhesion kinase, and matrix metalloproteinases [88].
During the metastatic process, MSCs can promote cancer progres-
sion by using homing and chemokines axis. Indeed, in a model of
prostate cancer, it was demonstrated that prostate cancer cells
secrete CXCL16 which recruits bone marrow-derived MSCs via the
axis CXCL16/CXCR6. Subsequently MSCs differentiate into CAFs
which, in turn, through the other axis CXCL12/CXCR4, induce EMT
[89] (Fig. 4). By contrast, some reports have suggested an inverse
role played by MSCs on the metastatic potential. For example,
although human MSCs increased tumor growth, they also signiﬁ-
cantly downregulated TGF-b with effects on the invasive and met-
astatic potential and as demonstrated in a model of
hepatocellular carcinoma [90].
TUMOR ANGIOGENESIS AND CSCS
Tumors create their own vascularization through different proc-
esses that are associated with angiogenesis, remodeling of pre-
existing vessels, recruitment, vascular mimicry (VM), and differen-
tiation of bone marrow endothelial precursors [46].
The vessel network is also a key component of the niche,
where CSCs can play a role following radio- and chemo-therapies.
As an example, treatment with the VEGF-A-inhibitor drug, such as
Bevacizumab, has been demonstrated to deplete the CSCs subpo-
pulation in an orthotopic model of glioma, which leads to signiﬁ-
cant inhibition of tumor growth [91].
Another example is head-and-neck squamous cell carcinoma,
where CSCs have been shown to localize in the proximity of tumor
vessels, and where they are maintained by growth factors that are
secreted by endothelial cells [92]. On the other hand, in colorectal
cancer, it seems that CSCs population is better maintained by
hypoxic conditions, leading to the formulation of the hypoxic
niche hypothesis [93]. Moreover, MSCs that produce VEGF,
Angiopoietin-1 (Ang-1) and other pro-angiogenic factors, could
differentiate into pericytes and endothelial cells, which supports
tumor vascularization and growth. In a colorectal cancer model, it
has been shown that primary human MSCs secrete a series of
pro-angiogenic factors, such as interleukin-6 (IL-6) and
angiopoietin-1, inducing also cancer cells to produce endothelin-1
(ET-1), thereby promoting tumor angiogenesis (Fig. 5). ET-1 acti-
vated Akt and ERK pathways in endothelial cells which led to the
induction of tumor angiogenesis [93]. In a breast cancer model,
both endothelial cells and adipose-derived MSCs interplayed to
give rise to pericytes and mature vessels [94]. This interconnection
could act via intercellular or paracrine signals, and probably
through angiopoietins signal, since adipose-derived MSCs have
been shown to express Angiopoietin-1 while endothelial cells
expressed their corresponding receptors Tie1 and 2 [94]. However,
there are opposite demonstrations of a negative role of MSCs on
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angiogenesis. It has been showed that murine MSCs could release
reactive oxygen species which damage endothelial cells, and that
MSCs could affect vessels formation in a melanoma model [95].
In the case of the severe hypoxia within the tumor, several
growth factors such as PDGF and VEGF are strongly expressed rep-
resenting crucial chemotactic and mitogenic factors for MSC.
Thus, MSC migrate toward tumor and promote vasculogenesis by
an autonomous VEGF production and, therefore, further
empower the pro-angiogenic potential of tumors. Another pro-
cess that deserves to be cited is the so called “vascular mimicry.”
In this, cancer creates itself channels for ﬂuid transport independ-
ent of typical modes of angiogenesis. It has been demonstrated
that uveal melanoma cells are able to dedifferentiate in endothe-
lial like cells losing the speciﬁc melanoma markers and acquiring
those of endothelial cells. Considering the CSCs model, it has been
also hypothesized that a fraction of CSCs could differentiate in
cells with VM phenotype. Vartanian et al. [96] have demonstrated
that melanoma cells were able to increase the vasculogenic
potential of MSCs by VM. In fact, MSCs derived from adipose tis-
sues of C57BL/6 mice in cocultured with melanoma cells formed
vascular-like network on Matrigel. MSCs alone was not able to
form capillary like structures. This is the ﬁrst direct evidence that
melanoma cells instruct MSCs to participate in VM. Now, the con-
cept of VM and its importance in interaction of MSCs and cancer
cells is receiving improved attention in the ﬁeld of angiogenesis
especially for angiogenic therapies.
INFLUENCE OF CSCS AND MSCS ON MULTIDRUG RESISTANCE
Among several mechanisms, one of major importance is the multi-
drug resistance (MDR) one. Indeed, the inefﬁcacy of anticancer
treatment may be ascribed to a reduced drug uptake, increase in
drug extrusion from the cancer cell, increase drug inactivation or
decreased activation, decrease in the formation of drug-activated
complex, and increase of repair of drug induced damage. Several
studies reported that CSCs are resistant to conventional therapies
in many types of solid tumors. CSCs present some transmembrane
transporters such as ABC transporters (ATP-binding cassette) fam-
ily of molecules that actively pump the drug outside the cell. This
unique property is also used as a method to isolate stem-like cells
from tumor cells [1, 97]. CSCs also possess some enzymes, like
ALDH and glutathione transferase (GST), that are capable to
metabolize and inactivate anticancer agents such as platinum salts
and others. Several signaling pathways have been linked to the
drug resistance of CSCs, among which Wnt, Notch, Hedgehog. A
number of studies conﬁrmed the capacity of MSCs to confer drug
and radiation resistance to cancer cells. In a model of breast can-
cer, adipose-derived MSCs provide resistance to trastuzumab via
the activation of c-Src and the downregulation of the phosphatase
and tensin homolog [98]. The methylation of the tumor suppres-
sor genes promoters has been shown to transform MSCs (from
human healthy donors’ bone marrow and umbilical cord blood)
into CSCs, that have tumor-initiating and drug resistance capaci-
ties in in vivo models [99]. In general, MSCs can modulate the sen-
sitivity of cancer cells to chemotherapeutic agents through the
production of factors like polyunsaturated fatty acids, PDGF-C,
Figure 5. Model of a mechanism inducing tumor angiogenesis and
involving MSCs. These cells can produce a series of angiogenic fac-
tors such as angiopoietin-1 and IL-6 that induce the secretion of
VEGF and other angiogenic molecules promoting tumor angiogene-
sis. Abbreviations: FGF, ﬁbroblast growth factor; MSC, mesenchymal
stem cell; PDGF, platelet-derived growth factor; VEGF, vascular
endothelial growth factor.
Figure 4. Model of a possible mechanism that enables cancer cells to migrate and form new tumors. Cancer cells produce CXCL16 that, in
turn, induce the recruitment of MSCs in tumor site. CXCL16 binds its receptor, CXCR6 on MSCs. The latters are converted in CAFs producing
high levels of CXCL12. CXCL12, in turn, induces cancer cells to undergo to an EMT that heightens CXCR4 expression in cancer cells. CXCR4
expression enables metastasis. Abbreviations: CAF, cancer-associated ﬁbroblast; EMT, epithelial-to-mesenchymal transition; MSC, mesenchy-
mal stem cell.
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hepatocyte growth factor, nitric oxide, and interleukin-17A (IL-
17A) [100].
PERSPECTIVES: EXPLOITING MSCS FOR CANCER THERAPY
It has been demonstrated that, after murine MSCs transplantation
in animal models, sarcoma developed [101]. In a same manner, it
has been reported a case of a late local recurrence of human
osteosarcoma which occurred 13 years after the initial pathology
and 18 months after a lipoﬁlling procedure [40]. Therefore, it is
unclear if MSCs have an effect mainly tumor promoting or sup-
pressive. Discrepancy between these results may arise also from
isolation techniques and growth conditions of MSCs, experimental
design in phenotype characterization, heterogeneity in MSCs pop-
ulation, individual donor variability, and injection time of MSCs in
each experiment. Thus, it is important to standardize experimental
protocols. Although MSCs could be a promising cell source in cell
therapy, these observations and results question the safety and
therapeutic procedure in clinical applications of MSCs grafting,
and particularly for patients with cancer history. Therefore, the
clinical application of MSCs for cancer treatment is still challeng-
ing. Due to contrasting results regarding the roles played by MSCs
in cancer, both in animal and human models, and it remains difﬁ-
cult to establish what are the mechanisms implicated in cancer
development due to MSCs. Some studies have showed a tumor
suppressive effect of MSCs, others reported a tumor supportive
potential. Indeed, in an interesting paper exploring in vivo and in
vitro effects of adipose-derived MSCs on melanoma and glioblas-
toma cell lines, MSCs have been shown to produce similar pro-
inﬂammatory and pro-angiogenic soluble factors; however, conse-
quent effects were different with demonstrated pro-survival effect
on melanoma cells and antitumor effect on glioblastoma cells
[102]. It seems that the result could depend on the speciﬁc
response of tumor cells to MSCs paracrine signals and on the type
of tumor [103]. Moreover, cancer cells can release factors that
induce and maintain the stem cell phenotype in MSCs, block their
differentiation, and therefore support tumor proliferation, angio-
genesis and metastases formation. These lead to the creation of a
stem cell microenvironment that could help reinforce drug resist-
ance. In fact, an important issue to consider derives from what we
have demonstrated on the inﬂuence of cancer cells on MSCs [19].
We could hypothesize that when cancer cells remained present
within the tissue after surgery, these cells could recruit resident or
bone-marrow derived MSCs that promote recurrence, tumor
induction by disrupting cancer “dormancy.” In efforts to ﬁnd new
therapeutic strategies against tumors, it has been proposed to use
MSCs as vehicles to deliver drugs directly to cancer cells [104]. For
example, human MSCs transduced with an adenoviral expression
vector carrying the human IFN gene, suppressed the growth of
lung metastasis in an in vivo model of breast and lung cancers.
MSCs were isolated from the bone marrow of healthy donors
undergoing bone marrow harvest for use in allogeneic bone mar-
row transplantation. Another consequence of such a strategy is
the possibility to deliver directly tumor agents using other routes
of administration which would be more toxic to tumors [104].
Currently, several phase I and phase II trials utilizing MSCs as anti-
cancer treatment are ongoing [105]. As an example, a phase I trial
is currently recruiting patients with localized prostate cancer, using
allogeneic bone marrow as source of MSCs [NCT01983709], while
another phase I/II trial, which uses adipose derived MSCs, is now
active although not yet recruiting for patients with recurrent ovar-
ian cancer [NCT02068794]. Thus, it is crucial that researchers con-
tinue to examine the roles and mechanisms of MSCs in tumor
progression to harness the therapeutic potential of MSCs and to
control cancer progression.
CONCLUSION
Looking at available evidence, we do not have clear data about
the activity of MSCs on cancer cells, due to contradicting effects
that could be favorable or unfavorable for tumor’s growth.
Unfortunately, the processes are complicated by the nature of cel-
lular interactions between MSCs and cancer cells that include
membrane fusion or mitochondria exchange, growth factors, or
metabolites that shape the relationship of MSCs with tumor cells
even more enigmatic. In this context, there is no doubt that cau-
tion should be used in the ﬁeld of regenerative medicine when for
example adipose tissue is used in patients with cancer history. In
fact, if cancer cells persist following surgery, they will most likely
induce resident MSCs to promote tumor angiogenesis, thus favor-
ing tumor growth. Although, there are no methods which can
allow the microscopic detection of diseases, clinicians must use
MSCs grafting only after meticulous analyses of possible cancer.
Future challenges will focus on understanding how MSCs are able
to affect all phases of carcinogenesis, from CSC arising, angiogene-
sis, tumor growth, and metastasis, to the MDR. Moreover, due to
the fact that MSCs migrate toward tumor sites, it will be interest-
ing and attractive to perform studies that consider MSCs as drug
carriers. To achieve a better treatment of patients, future clinical
approaches will need to use strategies that inhibit the dialog and
the relationship between MSCs and cancer cells.
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